The Motley Fool
13 Jun 2026, 04:15 UTC · 1h ago
Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
The Motley Fool
13 Jun 2026, 04:15 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Boston Scientific CEO Michael Mahoney indicated the company will likely report flat dollar growth for the second and third quarters. — Flat growth projections for two consecutive quarters signal a significant stagnation in momentum and immediate revenue headwinds.
-0.60Boston Scientific has repeatedly lowered organic revenue guidance throughout the year, most recently reducing the 2026 outlook to between 6.5% and 8%. — A pattern of walking back growth expectations erodes investor confidence in management's visibility and the company's long-term trajectory.
-0.50The decline in growth is partially attributed to the decreasing usage of Watchman stand-alone heart implant procedures. — This identifies a specific product-level failure or market shift affecting a key revenue driver.
-0.30Continue reading
6 related stories
Top 3 movers · tap to explore
Despite the stock's decline, 27 out of 31 analysts maintain a buy rating with a consensus price target of $78, suggesting a potential 65% upside. — Strong analyst support provides a psychological floor and potential catalyst for a recovery if results improve.
+0.20Which stocks this story touches
The company has seen significant share price declines and has repeatedly lowered growth expectations and revenue guidance.
Mentioned only as a peer for valuation comparison and as a recommended holding by the author's firm.
Mentioned only as a peer for valuation comparison and as a recommended holding by the author's firm.
[mutual] Both companies are cited as comparable medical device stocks.
[mutual] Boston Scientific is compared to Abbott Laboratories as being in the same medical device stock category.
[mutual] Boston Scientific is compared to Medtronic as being in the same medical device stock category.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
4h ago
